These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32649208)

  • 1. Exploring the Impact of Surfactant Type and Digestion: Highly Digestible Surfactants Improve Oral Bioavailability of Nilotinib.
    Koehl NJ; Holm R; Kuentz M; Jannin V; Griffin BT
    Mol Pharm; 2020 Sep; 17(9):3202-3213. PubMed ID: 32649208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Insights into Using Lipid Based Suspensions for 'Brick Dust' Molecules: Case Study of Nilotinib.
    Koehl NJ; Holm R; Kuentz M; Griffin BT
    Pharm Res; 2019 Feb; 36(4):56. PubMed ID: 30796596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chase Dosing of Lipid Formulations to Enhance Oral Bioavailability of Nilotinib in Rats.
    Koehl NJ; Holm R; Kuentz M; Griffin BT
    Pharm Res; 2020 Jun; 37(7):124. PubMed ID: 32524365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and optimization of nilotinib self-micro-emulsifying drug delivery systems to enhance oral bioavailability.
    Zakkula A; Gabani BB; Jairam RK; Kiran V; Todmal U; Mullangi R
    Drug Dev Ind Pharm; 2020 Mar; 46(3):498-504. PubMed ID: 32067499
    [No Abstract]   [Full Text] [Related]  

  • 5. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
    Feeney OM; Williams HD; Pouton CW; Porter CJ
    J Control Release; 2014 Oct; 192():219-27. PubMed ID: 25058571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion.
    Mohsin K
    AAPS PharmSciTech; 2012 Jun; 13(2):637-46. PubMed ID: 22547370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kolliphor surfactants affect solubilization and bioavailability of fenofibrate. Studies of in vitro digestion and absorption in rats.
    Berthelsen R; Holm R; Jacobsen J; Kristensen J; Abrahamsson B; Müllertz A
    Mol Pharm; 2015 Apr; 12(4):1062-71. PubMed ID: 25679417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone.
    Sek L; Boyd BJ; Charman WN; Porter CJ
    J Pharm Pharmacol; 2006 Jun; 58(6):809-20. PubMed ID: 16734982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis.
    Larsen A; Holm R; Pedersen ML; Müllertz A
    Pharm Res; 2008 Dec; 25(12):2769-77. PubMed ID: 18592356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
    McEvoy CL; Trevaskis NL; Feeney OM; Edwards GA; Perlman ME; Ambler CM; Porter CJH
    Mol Pharm; 2017 Dec; 14(12):4525-4538. PubMed ID: 29076741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs.
    Holm R; Jørgensen EB; Harborg M; Larsen R; Holm P; Müllertz A; Jacobsen J
    Eur J Pharm Sci; 2011 Mar; 42(4):416-22. PubMed ID: 21256961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs.
    Cuiné JF; McEvoy CL; Charman WN; Pouton CW; Edwards GA; Benameur H; Porter CJ
    J Pharm Sci; 2008 Feb; 97(2):995-1012. PubMed ID: 18064698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats.
    Boyd BJ; Khoo SM; Whittaker DV; Davey G; Porter CJ
    Int J Pharm; 2007 Aug; 340(1-2):52-60. PubMed ID: 17467935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enabling superior drug loading in lipid-based formulations with lipophilic salts for a brick dust molecule: Exploration of lipophilic counterions and in vitro-in vivo evaluation.
    Sirvi A; Jadhav K; Sangamwar AT
    Int J Pharm; 2024 May; 656():124108. PubMed ID: 38604540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation.
    Nguyen TH; Hanley T; Porter CJ; Larson I; Boyd BJ
    J Pharm Pharmacol; 2010 Jul; 62(7):856-65. PubMed ID: 20636873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity.
    Jannin V; Chevrier S; Michenaud M; Dumont C; Belotti S; Chavant Y; Demarne F
    Int J Pharm; 2015 Nov; 495(1):385-392. PubMed ID: 26364710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation.
    Han SF; Yao TT; Zhang XX; Gan L; Zhu C; Yu HZ; Gan Y
    Int J Pharm; 2009 Sep; 379(1):18-24. PubMed ID: 19508887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of lipid-based excipients and their composition on the bioavailability of antiretroviral self-emulsifying formulations.
    Chudasama A; Patel V; Nivsarkar M; Vasu K; Shishoo C
    Drug Deliv; 2015; 22(4):531-40. PubMed ID: 24601856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using in vitro lipolysis and SPECT/CT in vivo imaging to understand oral absorption of fenofibrate from lipid-based drug delivery systems.
    Tran T; Bønløkke P; Rodríguez-Rodríguez C; Nosrati Z; Esquinas PL; Borkar N; Plum J; Strindberg S; Karagiozov S; Rades T; Müllertz A; Saatchi K; Häfeli UO
    J Control Release; 2020 Jan; 317():375-384. PubMed ID: 31765705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linking
    Nguyen V; Bevernage J; Darville N; Tistaert C; Van Bocxlaer J; Rossenu S; Vermeulen A
    Mol Pharm; 2021 Mar; 18(3):952-965. PubMed ID: 33400546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.